Chronic thromboembolic pulmonary hypertension: anticoagulation and beyond

Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):478-484. doi: 10.1182/hematology.2021000282.

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication in pulmonary embolism (PE) survivors, characterized by chronic vascular occlusion and pulmonary hypertension. The identification and diagnosis of CTEPH requires a stepwise approach, starting with symptom evaluation, functional evaluation, screening imaging, and progressing to interventional hemodynamic assessment. On the backbone of anticoagulation, CTEPH management necessitates a multidisciplinary approach. Surgical pulmonary thromboendarterectomy (PTE) is the only potentially curative option. In nonoperable disease or residual disease after PTE, interventional balloon pulmonary angioplasty and/or pulmonary-vasodilator therapies can be offered, in collaboration with interventional and vascular pulmonary colleagues. As it is a disease that can cause high morbidity and mortality, CTEPH requires a high index of suspicion to diagnose and treat in patients following PE.

Publication types

  • Case Reports

MeSH terms

  • Angioplasty, Balloon
  • Anticoagulants / therapeutic use*
  • Chronic Disease
  • Disease Management
  • Endarterectomy
  • Humans
  • Hypertension, Pulmonary / complications*
  • Hypertension, Pulmonary / diagnosis
  • Hypertension, Pulmonary / drug therapy
  • Hypertension, Pulmonary / therapy*
  • Male
  • Middle Aged
  • Pulmonary Embolism / complications*
  • Pulmonary Embolism / diagnosis
  • Pulmonary Embolism / drug therapy
  • Pulmonary Embolism / therapy*

Substances

  • Anticoagulants